Ertugliflozin for treatment of patients with Type 2 diabetes mellitus

ABSTRACT

Introduction: Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. Inhibition of the sodium––glucosecotransporter-2 (SGLT2) can increase urinary glucose excretion and decrease plasma glucose levels in an insulin-independent manner. Ertugliflozin is a highly selective inhibitor of SGLT2, and was approved in the US for the treatment of adults with T2DM.

Areas covered: In this paper, the mechanism of action, pharmacokinetics, clinical efficacy, safety, etc., of ertugliflozin have been introduced. Expert commentary: Ertugliflozin offers a novel, therapeutic approach to T2DM. Advantages of ertugliflozin include reduction in glycated hemoglobin, weight loss and blood pressure lowering with a low risk of hypoglycemia. The main adverse effects likely to be seen are genital fungal infections. Studies show that there is no increased risk of cardiovascular disease, but studies focusing on longer duration outcome are still essential.

KEYWORDS:

• Ertugliflozin
• glycated hemoglobin
• genital fungal infection
• sodium—glucosecotransporter-2
• Type 2 diabetes mellitus

Declaration of interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

A reviewer on this manuscript has disclosed that they received honoraria for lectures from Astrazeneca, Boehringher, and Merck Sharp & Dohme. I received grant for IIS from Boehringher and Astrarzeneca.

Additional information

Funding

This manuscript was not funded.